Takeuchi S, Saitoh H
Department of Urology, Saitama Medical Center of Saitama Medical School.
Nihon Rinsho. 1998 Aug;56(8):2077-81.
The levels of probable markers of bony metastatic disease were measured to evaluate their efficacy as predictors of disease and therapeutic outcome. Urinary pyridinoline and deoxypyridinoline were measured in patients with benign prostatic hyperplasia, clinically localized prostate cancer and prostate cancer with bone metastases. Also, urinary pyridinoline and deoxypyridinoline were compared in 2 groups of patients with metastatic prostate cancer of the bone who demonstrated progression or positive response to treatment. Urinary pyridinoline and deoxypyridinoline were determined by high performance liquid chromatography and were normalized to urinary creatinine. Levels of urinary pyridinoline and deoxypyridinoline in urine in patients with bony metastatic prostate cancer were significantly greater than levels in patients with benign prostatic hyperplasia or localized prostate cancer. Serial measurement of urinary pyridinoline and deoxypyridinoline was correlated with a positive response to treatment (decreased) and with clinical progression of disease (increased) before detection of new bone lesions by bone scintigraphy. Measurement of urinary pyridinoline and deoxypyridinoline may provide a useful marker of prostate cancer metastatic to bone and may be useful in monitoring the response to treatment.
为评估骨转移性疾病可能的标志物作为疾病预测指标和治疗结果指标的有效性，对其水平进行了测量。在良性前列腺增生、临床局限性前列腺癌以及伴有骨转移的前列腺癌患者中，测量了尿吡啶啉和脱氧吡啶啉。此外，在两组出现病情进展或对治疗有阳性反应的骨转移性前列腺癌患者中，对尿吡啶啉和脱氧吡啶啉进行了比较。尿吡啶啉和脱氧吡啶啉通过高效液相色谱法测定，并以尿肌酐进行标准化。伴有骨转移的前列腺癌患者尿液中尿吡啶啉和脱氧吡啶啉的水平显著高于良性前列腺增生或局限性前列腺癌患者。在通过骨闪烁显像检测到新的骨病变之前，连续测量尿吡啶啉和脱氧吡啶啉与治疗的阳性反应（降低）以及疾病的临床进展（升高）相关。测量尿吡啶啉和脱氧吡啶啉可能为前列腺癌骨转移提供有用的标志物，并且可能有助于监测治疗反应。
